4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Psoriasis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 993 ongoing clinical trials involving Psoriasis
Of the 993 trials,308 trials are in Phase III
Furthermore, 302 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Psoriasis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Psoriasis, an immunology condition. The largest number of ongoing clinical trials for Psoriasis is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Psoriasis-related drug trials.

Johnson & Johnson: The leading ongoing Psoriasis related clinical trial sponsor

Johnson & Johnson is the top sponsor for Psoriasis-related ongoing clinical trials.

AbbVie Inc, Guangdong Provincial Hospital of Traditional Chinese Medicine, Amgen Inc, and Sun Pharmaceutical Industries Ltd are among other notable clinical trial sponsors involved in Psoriasis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Psoriasis

Adalimumab (Humira), stekinumab (Stelara), and Etanercept (Enbrel, Enbrel PFS) are among the key marketed drugs involving Psoriasis.

Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). It functions via Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor mechanism of action. Adalimumab is formulated as an injection for subcutaneous route of administration. Adalimumab is marketed for the treatment of several indications including Pyoderma Gangrenosum, Axial Spondyloarthritis, Hidradenitis Suppurativa, Uveitis, Ankylosing Spondylitis (Bekhterev's Disease), Psoriatic Arthritis, Psoriasis, Ulcerative Colitis, Rheumatoid Arthritis, Crohn's Disease (Regional Enteritis), Anterior Uveitis, Behcet Disease, Intermediate Uveitis, Plaque Psoriasis (Psoriasis Vulgaris), Polyarticular Juvenile Idiopathic Arthritis (PJIA), and Posterior Uveitis. It was first approved in 2002 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including AbbVie Inc, Eisai Co Ltd, and Abbott Laboratories.

Ustekinumab (Stelara) is a human monoclonal antibody used as immunosuppressant. It functions via Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Inhibitor; Interleukin 23 Subunit Alpha (Interleukin 23 Subunit p19 or IL23A) Inhibitor mechanism of action. It is produced by a recombinant DNA technology. It is formulated as a injectable solution for injection, powder for solution and solution for injection in pre-filled syringe and is administered by subcutaneous route and intravenous administration and injectable concentrate solution for subcutaneous route of administration. Ustekinumab is marketed for the treatment of several indications including Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), and Plaque Psoriasis (Psoriasis Vulgaris). Ustekinumab was first approved in 2008 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including Janssen Biotech Inc, J-C Health Care Ltd, and Johnson & Johnson.